

# Development of YH32367, a novel HER2/4-1BB bispecific antibody for the treatment of HER2 expressing solid tumors



ONCOLOGY	Phase 2
Product Type	Antibody
Indication	<ul style="list-style-type: none"> <li>• Primary Indication: HER2-positive biliary tract cancer (BTC)</li> <li>• Other Indications: HER2-expressing solid tumors</li> </ul>
Target	HER2 expression
MoA(Mechanism of Action)	<ul style="list-style-type: none"> <li>• Bispecific T cell engager binds HER2 on tumor cells and 4-1BB on T cells</li> <li>• Enhances T cell activation and survival through 4-1BB stimulation</li> <li>• Blocks HER2-mediated tumor cell growth signaling</li> <li>• Induces ADCC by activating CD16 and 4-1BB in NK cells</li> </ul>
Competitiveness	<ul style="list-style-type: none"> <li>• Durable clinical efficacy due to tumor-specific immune-memory</li> <li>• Significantly lower toxicity compared to HER2-ADC</li> <li>• Potential for development in combination with standard treatment due to its favorable safety profile</li> </ul>
Development Stage	Phase 2
Route of Administration	<ul style="list-style-type: none"> <li>• Dosing: every 3 weeks (Q3W)</li> <li>• Route of administration: intravenous infusion over 30-90 minutes</li> </ul>

*Any unauthorized distribution or reproduction of this material is strictly prohibited.*